Effect of changing therapy from agalsidase beta to agalsidase alfa in patients with Fabry disease

被引：0
|
作者：
West, M [1 ]
Lemoine, K [1 ]
机构：
[1] Dalhousie Univ, Dept Med, Halifax, NS, Canada
来源：
ACTA PAEDIATRICA | 2006年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [41] The effect of enzyme replacement therapy with agalsidase alfa on cerebrovascular disease in a female heterozygote with Fabry disease
    Clarke, JTR
    Jaigobin, C
    Wherrett, JR
    Iwanochko, RM
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) : 581 - 581
  • [42] Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal) (vol 14, pg, 779, 2012)
    Tsuboi, Kazuya
    Yamamoto, Hiroshi
    GENETICS IN MEDICINE, 2012, 14 (08) : 752 - 752
  • [43] Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report
    Cakmak, Mehmet Erdem
    NORTHERN CLINICS OF ISTANBUL, 2024, 11 (01) : 88 - 90
  • [44] Update on role of agalsidase alfa in management of Fabry disease
    Ramaswami, Uma
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 : 155 - 173
  • [45] Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease
    Feriozzi, Sandro
    Schwarting, Andreas
    Sunder-Plassmann, Gere
    West, Michael
    Cybulla, Markus
    AMERICAN JOURNAL OF NEPHROLOGY, 2009, 29 (05) : 353 - 361
  • [46] Fabry disease: overall effects of agalsidase alfa treatment
    Beck, M
    Ricci, R
    Widmer, U
    Dehout, F
    de Lorenzo, AG
    Kampmann, C
    Linhart, A
    Sunder-Plassmann, G
    Houge, G
    Ramaswami, U
    Gal, A
    Mehta, A
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (12) : 838 - 844
  • [47] Agalsidase alfa prevents the decline in renal function in patients with Fabry disease
    Schwarting, A
    Dehout, F
    Feriozzi, S
    Beck, M
    Mehta, A
    Widmer, U
    Sunder-Plassmann, G
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V248 - V248
  • [48] Agalsidase beta (recombinant human α-galactosidase A) therapy in paediatric patients with Fabry disease
    Wraith, J. E.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 28 - 28
  • [49] EFFECT AND TOLERABILITY OF AGALSIDASE ALFA WERE ASSESSED IN PATIENTS WITH FABRY DISEASE WHO WERE TREATMENT-NAIVE (NAIVE) OR PREVIOUSLY TREATED WITH AGALSIDASE BETA (SWITCH PATIENTS)
    Goker-Alpan, Ozlem
    Ibrahim, Jennifer
    Nedd, Khan
    Shankar, Suma
    Lein, Howard
    Barshop, Bruce
    Boyd, Ellen
    Holida, Myrl
    Hillman, Richard
    Ibrahim, Jennifer
    Mardach, Rebecca
    Wienreb, Neil
    Rever, Barbara
    Forte, Richard
    Desai, Alpana
    Wijatyk, Anna
    Chang, Peter
    Martin, Rick
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 316 - 316
  • [50] Safety of agalsidase alfa in patients with Fabry disease under 7 years
    Ramaswami, U.
    Parini, R.
    Kampmann, C.
    Beck, M.
    ACTA PAEDIATRICA, 2011, 100 (04) : 605 - 611
12345